Invesco Biotechnology & Genome ETF
PBE
97 hedge funds and large institutions have $73M invested in Invesco Biotechnology & Genome ETF in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 3 closing their positions.
217% more capital inflows, than outflows
Capital inflows: $7.68M | Capital outflows: $2.42M
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
3% more funds holding
Funds holding: 94 → 97 (+3)
1.13% more ownership
Funds ownership: 23.81% → 24.94% (+1.1%)
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artemis Wealth Advisors
New York
|
+$4.15M |
| 2 |
Goldman Sachs
New York
|
+$1.02M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$659K |
| 4 |
Cypress Capital
Franklin,
Tennessee
|
+$287K |
| 5 |
LPL Financial
San Diego,
California
|
+$163K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.18M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$350K |
| 3 |
HBK Sorce Advisory
Erie,
Pennsylvania
|
-$204K |
| 4 |
Citigroup
New York
|
-$147K |
| 5 |
Morgan Stanley
New York
|
-$117K |
PBE Hedge Fund Activity: Q3 2021 in Review
97 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2021, worth a combined $73M — up 3.8% from $70.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PBE positions and 3 closed out — a net gain of 5 holders — while 12 added to existing stakes and 22 trimmed.
The largest buyer was Artemis Wealth Advisors, opening a new position worth an estimated $4.15M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.18M sold.
- 97 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2021, up from 94 in Q2 2021.
- Funds reported $73M of Invesco Biotechnology & Genome ETF stock for Q3 2021, up 3.8% quarter-over-quarter.
- 8 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2021 and 3 closed out, a net change of +5 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q3 2021 was Artemis Wealth Advisors, an estimated $4.15M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q3 2021 was Susquehanna International Group, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2021.